Introduction {#Sec1}
============

*Aspergillus* spores are ubiquitous, and once aerosolized, they may colonize the airways and related structures, such as the nose and facial sinuses \[[@CR1]\]. Further immunosuppression, such as severe and prolonged neutropenia, markedly increases the risk for invasive disease characterized by tissue invasion and secondary bloodstream dissemination \[[@CR1]\]. *Aspergillus fumigatus, Aspergillus flavus* and *Aspergillus niger* are responsible for the majority of invasive diseases \[[@CR2]--[@CR4]\]. Invasive aspergillosis is reported to occur in fewer than 1% of patients infected by human immunodeficiency virus (HIV), in 1--5% of liver transplant recipients, in 3--7% of allogenic bone marrow transplant recipients, but in up to 10% of patients with hematological malignancies or lung transplants, and as high as 14% of heart transplant recipients \[2--7\].

Invasive pulmonary aspergillosis accounts for 90--98% of invasive infections. Extra-pulmonary aspergillosis may be present in 25--60% of cases and is almost universally described in the context of disseminated diseases \[[@CR2], [@CR8]--[@CR15]\]. Although rarely documented before autopsy, these conditions usually result from bloodstream dissemination secondary to vascular invasion at the primary site of infection \[[@CR16]\]. Isolated extra-pulmonary aspergillosis located in the central nervous system, the skin, the liver, the urinary tract and the digestive tract has only been mentioned in case reports, but potential portals of entry other than the respiratory tract are speculative \[[@CR2], [@CR3], [@CR17]\]. We report two cases of primary invasive aspergillosis of the digestive tract and review the literature on *Aspergillus* spp. gastrointestinal involvement.

Methods {#Sec2}
=======

Our objective was to identify lower digestive tract involvement reported in series of invasive aspergillosis and secondly, to identify previously-published cases with a possible diagnosis of aspergillosis at this site. We searched the English-language literature from 1960 to 2005, December, for reports of aspergillosis with digestive tract involvement through an electronic search of the MEDLINE (National Library of Medicine, Bethesda, MD, USA) database using key words "aspergillosis", "invasive aspergillosis", "disseminated disease", "extra-pulmonary aspergillosis" and "digestive tract aspergillosis" and the reference lists of retrieved articles, including reviews. Cases were included if the diagnosis of primary invasive aspergillosis of the bowel was defined as histologic evidence of *Aspergillus* hyphae in a segment of the bowel biopsy with mucosal alteration and tissue destruction and/or tissue invasion with microvascular involvement. Cases with isolated involvement of the upper digestive tract were excluded.

Case Reports {#Sec3}
============

Case 1 {#Sec4}
------

A 65-year-old man presented with septic shock attributed to *Proteus vulgaris* primary bacteremia without clinical focus of infection. It occurred on day 6 after admission for transformation of a myelodysplasic syndrome into acute myeloid leukemia for which he received high-dose cytarabine with idarubicin as induction therapy. He responded to empirical broad spectrum antibiotics within 48 h. Fever recurred on day 10 with abdominal pain, and septic shock developed the following day. On day 12, emergency laparotomy showed a necrotic mass of the jejunum which was resected. Direct histologic examination showed branched hyphae with transmural involvement and vascular invasion. After transient improvement for 48 h, multiple organ failure developed. Macroscopic *Aspergillus* colonies appeared on the surgical stomas at day 14 and the patient died on day 16 despite intensive support and amphotericin B therapy. Autopsy showed disseminated aspergillosis with several new segmental necroses of the small bowel and multiple emboli of fungal material in several organs including the lungs. A detailed examination of the lungs did not show any consolidated aera. *A. fumigatus* was isolated from peroperative and autopsy cultures.

Case 2 {#Sec5}
------

A 52-year-old man presented with septic shock due to *Pseudomonas aeruginosa* primary bacteremia without clinical focus of infection. The symptoms occurred on day 14 after admission for transformation of a myelodysplasic syndrome into acute myelocytic leukemia for which he received high-dose cytarabine with idarubicin as induction therapy. He responded to empirical broad spectrum antibiotics within 48 h. Fever relapsed on day 25 with abdominal pain. A CT scan excluded lung infiltrates and confirmed the diagnostic of typhlitis. On day 30, a laparotomy performed for acute peritonitis revealed four masses in the ileon. Histology showed branched hyphae (*A. fumigatus* by culture) with transmural involvement and vascular invasion (Figure [1](#Fig1){ref-type="fig"}). A second CT scan excluded lung involvement. Therapy with amphotericin B (2 g over 28 days) was initiated and the patient made a full recovery on day 45. Two months later he died from hemorrhage during induction therapy for autologous bone marrow transplantation. Autopsy showed no recurrence of aspergillosis. Figure 1Giemsa-Silver coloration (original magnification, ×200). Diffuse hemorrhagic necrosis surrounding an ulceration of the wall of a surgically-resected segment of jejuna with loss of the architectural organization of the layers. Vascular occlusion by branched *A. fumigatus* hyphae (black structures).

Results {#Sec6}
=======

Of 23 cases of possible primary invasive aspergillosis of the digestive tract identified in the literature \[[@CR5], [@CR12]--[@CR14], [@CR18]--[@CR22]\], details were available for only eight of them \[[@CR23]--[@CR30]\] (Table [1](#Tab1){ref-type="table"}). Table 1Selected characteristics of ten patients with primary digestive invasive aspergillosis.Case reportCase reportCase 37-1976 \[[@CR23]\]Weingard \[[@CR24]\]Cohén \[[@CR25]\]Marterre \[[@CR26]\]Catalano \[[@CR27]\]Shah \[[@CR28]\]Sousa \[[@CR29]\]Trésallet \[[@CR30]\]Age (years)63524 weeks3833858682157Underlying diseaseAMLAMLAMLALLAMLAMLAMLAMLAplastic anemiaLymphomaDocumentationHistology + cultureHistology + cultureHistology + cultureHistology + cultureHistology + cultureHistology + cultureHistology + cultureHistology + cultureHistology + cultureHistology + culturePrevious infectionBacteremiaBacteremiaBacteremiaBacteremiaFever of unknown originBacteremiaFever of unknown originSuspected line infectionFever of unknown originFever of unknown originMicroorganisms*Proteus vulgarisPseudomonas aeruginosaStaphylococcus aureusKlebsiella oxytoca; Enterococcus faecatis*---*Pseudomonas aeruginosa*------------ChemotherapyCytarabine, idarubicinCytarabine, idarubicinCytarabine, daunorubicinCytarabine, adriamicinCytarabine, daunorubicinVincristinCytarabine, daunorubicinCytarabine, idarubicinCyclosporin ACytarabine, etoposideDays after chemotherapy13148 (second cycle)19 (second cycle)2423151128Not specified (induction)Neutropenia at diagnosisYesYesYesYesYesNoYesYesYesYesAntifungal prophylaxisNoNoNoNot specifiedNot specifiedNot specifiedYesNot specifiedNot specifiedNot specifiedNumber of previous antibiotics333253Several4Several3Antimicrobial agentsCiprofloxacin, gentamicin, metronidazoleMeropenem, amikacin, teicoplaninCarbenicillin, gentamicin, oxacillinCeftazidime, amikacinCeftazidime, amikacinCeftazidime, tobramycin, ticarcillinNot specifiedCefepime, metronidazole, gentamicin, vancomycinNot specifiedImipenem, gentamicin, metronidazolePrior exposure to amphotrericin BNoYesNoNoYesNoNoNoNoNoClinical presentationRelapsing fever, ileus, peritonitisRelapsing fever, ileus, bloody diarrhea, peritonitisRelapsing fever, peritonitisRelapsing fever, ileus, bloody diarrhea, peritonitisRelapsing fever, watery diarrhea, peritonitisRelapsing fever, ileus, peritonitisRelapsing fever, digestive hemorrhage, peritonitisPersisting fever, peritonitisPersisting fever, peritonitisPersisting fever, peritonitisSerology------------------------------Antigenemia---------------------------6.2 ng/ml (ELISA)Secondary disseminationLungNoLung, liverLungLung, liverNoNot specifiedNot specifiedNot specifiedNoNo. of surgical interventions1211251111Days after chemotherapy12138192423151428Not specifiedBowel excisionYesYesYesYesYesYesYesYesYesYesAntifungal treatmentAmphotericin BAmphotericin B------------Not specifiedNot specifiedNot specifiedVoriconazoleOutcome at 28 daysDeathSurvivalDeathSurvivalDeathSurvivalDeathDeathDeathSurvivalAML: acute myeloid leukemia; ALL: acute lymphoid leukemia

Nine of ten patients presented with acute hematologic malignancy, and eight received high-dose cytarabine known to be associated with diffuse mucositis. Six presented a prior episode of bacteremia during neutropenia. All ten received a combination of antibiotics with broad spectrum coverage within the 2 weeks before the onset of the abdominal complication, and all presented with abdominal symptoms suggestive of typhlitis, with digestive hemorrhage in three. Laparotomy was performed for acute peritonitis and showed transmural necrosis of the small bowel requiring segmental resection in all cases. Histology consisted in multiple lesions from superficial ulceration to transmural necrosis and vascular thrombosis with tissue invasion by branched hyphae of *Aspergillus* spp. were present in all cases (Figure [1](#Fig1){ref-type="fig"}). All cases were characterized by the absence of pulmonary disease at time of histologically-confirmed digestive aspergillosis. Serology and antigenemia was either not available or not performed in all but one cases and death occurred in six of ten patients (60%).

Of 155 clinical studies retrieved from our review of the literature, 25 included more than 25 cases of invasive aspergillosis in non-HIV infected adult patients with details on the distribution of organs involved (Table [2](#Tab2){ref-type="table"}). There were 6 autopsy series \[[@CR11]--[@CR13], [@CR18], [@CR31], [@CR32]\], 11 retrospective series \[[@CR5], [@CR14], [@CR15], [@CR19], [@CR33]--[@CR39]\] and 8 prospective series \[[@CR20]--[@CR22], [@CR40]--[@CR44]\]. Table 2Invasive aspergillosis: organ distribution and mortality; 1960--2005. Studies including more than 25 adult patients.Organ distributionAuthorsNMortalityLungDisseminatedCNSDigestivePrimary digestive*Autopsy*Young et al. \[[@CR12]\]98100%92 (94%)34 (35%)13 (13%)21 (21%)3 (3%)Meyer et al. \[[@CR13]\]93100%90 (98%)23 (35%)9 (10%)9 (10%)1 (1%)Boon et al. \[[@CR11]\]32100%32 (100%)20 (63%)16 (50%)15 (53%)0Vogeser et al. \[[@CR18]\]27100%23 (85%)16 (59%)12 (44%)7 (26%)1 (4%)Vogeser et al. \[[@CR31]\]48100%41 (85%)28 (58%)21 (44%)1 (2%)0Hori et al. \[[@CR56]\]107100%105 (98%)52 (52%)22 (21%)12 (11%)0Total405100%383 (95%)176 (43%)93 (23%)67 (17%)5 (1%)*Retrospectiva*Fisher et al. \[[@CR14]\]9188%83 (91%)20 (22%)13 (14%)5 (5%)1 (1%)Albelda et al. \[[@CR15]\]2662%26 (100%)NSNSNSNSMorrison et al. \[[@CR5]\]9362%87 (95%)43 (47%)21 (23%)NS1 (1%)Horvath and6952%49 (71%)NSNSNSNSDummer \[[@CR33]\]Janssen et al. \[[@CR34]\]2592%25 (100%)8 (32%)3 (12%)4 (28%)0Caillot et al. \[[@CR35]\]3727%37 (100%)8 (22%)000Kaiser et al. \[[@CR36]\]3597%33 (94%)8 (23%)1 (3%)00Abbasi et al. \[[@CR37]\]6685%46 (70%)23 (35%)9 (14%)00Lortholary et al. \[[@CR38]\]3145%28 (90%)7 (23%)4 (13%)00Nosari et al. \[[@CR39]\]6148%56 (92%)20 (33%)5 (8%)00Pagano et al. \[[@CR19]\]39151%332 (85%)NS37 ( 9%)9 (2%)4 (1%)Total92560% 555/925802 (87%)137/438 (31%)92/829 (11%)18/737 (2%)6/829 (0.7%)*Prospective*Ringden et al. \[[@CR40]\]3234%29 (91%)NSNS0NSDenning et al. \[[@CR20]\]7632%51 (67%)NS8 (11%)NS1 (1.3%)Stevens et al. \[[@CR21]\]12534%90 (72%)24 (19%)8 (6%)01 (0.8%)Denning et al. \[[@CR22]\]12364%106 (87%)33 (27%)10 (8%)01 (0.8%)Patterson et al. \[[@CR41]\]59551%330 (56%)148 (25%)34 (6%)NSNSDenning et al. \[[@CR42]\]11658%81 (70%)6 (5%)19 (16%)00Bowden et al. \[[@CR44]\]17453%107 (62%)NS12 (7%)NSNSHerbrecht et al. \[[@CR43]\]27735%240 (87%)15 (5%)10 (4%)NSNSTotal1,51847%1,034 (64%)226/1,236 (18%)101/1,486 (7%)0/396 (0%)3/440 (0.7%)716/1518*All studies*2,84859%2,219 (78%)539/2,079 (26%)296/2,720 (11%)85/1,538 (5.5%)14/1,674 (0.8%)1676/2848NS: not specified

The proportion of cases with a definite diagnosis was 100% in autopsy series and 73% (60--92%) and 65% (31--88%) in retrospective, and prospective series, respectively. The number of cases where the diagnosis was made before death increased from 23% (14--56%) in autopsy series, 76% (28--100%) in retrospective and 99.9% (99--100%) in prospective series. Mortality averaged 60% (27--88%) in retrospective and 47% (32--64%) in prospective series. This may indicate that patients included in prospective studies were less critically ill, or may have benefited from early presumptive antifungal therapy. Case-fatality rate was recently confirmed to be highest in bone marrow transplant recipients (87%) and among patients with central nervous system involvement (88%) \[[@CR45]\]. A large number of patients with solid organ transplant may have contributed to the higher survival rate reported in prospective series.

Invasive pulmonary aspergillosis accounted for a majority of cases. Bowel involvement during disseminated disease was not reported in prospective series and in only 2% of cases in retrospective series (0--28%). However, it was reported in 17% (2--53%) of cases included in the autopsy series. Apart from 14 cases for which no details were available, invasion of the digestive tract was always reported in the context of disseminated disease \[[@CR11]--[@CR14], [@CR18], [@CR20], [@CR21], [@CR34], [@CR40], [@CR46]\]. A mixed infection with *Candida* species was reported in series where more details were available \[[@CR12], [@CR47]\]. A digestive hemorrhage was reported in most cases, but was not considered specific.

Comment {#Sec7}
=======

Invasive aspergillosis is almost exclusively considered as a pulmonary disease with secondary hematogenous dissemination \[[@CR1], [@CR5]\]. Fungal infections of the small and large intestine are rare \[[@CR47]\]. However, *Aspergillus* spores are not only inhaled but also ingested, and isolated aspergillosis of the upper digestive tract has been described \[[@CR48]\]. In two reviews covering more than 3,000 cases collected from several hundreds of articles over three decades, *Denning* suggested that, although never demonstrated, the gastrointestinal tract may be considered as a potential portal of entry for *Aspergillus* spp. \[[@CR2], [@CR3]\].

In contrast to *Candida* spp., *Aspergillus* spores may not survive or meet favorable conditions to develop on the mucosal surfaces of the digestive tract. However, large ulcers, such as those described as occurring after high-dose cytarabine-related mucositis, may be colonized by *Aspergillus* spores \[[@CR48]\]. This may also be the case for patients developing a neutropenic or necrotizing enterocolitis, also referred to as typhlitis. This defines an abdominal complication occurring in neutropenia and induced by chemotherapy \[[@CR49]\]. It complicates 5--30% of treatments, including those with high-dose cytarabine, with variable clinical manifestations ranging from mild gastrointestinal symptoms to life-threatening intestinal necrosis with perforation and secondary peritonitis \[[@CR50], [@CR51]\]. The latter condition mandates a surgical approach and has been associated with mortality rates of over 50% \[[@CR52], [@CR53]\]. Although not specific, abdominal CT scan may be suggestive. The eventual value of Aspergillus serology and antigenemia has not been studied in this context. Diffuse dilatation with edema of the bowel walls, predominantly located in the caecum, with some degree of hemorrhage and necrosis are common pathological findings \[[@CR54]\]. As described in the ten above-mentioned cases, bowel necrosis is associated with the invasion of a poorly vascularized wall by gram-negative bacilli and yeast after breakdown of the normal flora \[[@CR52], [@CR55]\].

In conclusion, we report two cases of possible primary digestive aspergillosis. These two cases and the eight previously published suggest that the digestive tract may represent a portal of entry for *Aspergillus* species in immunocompromised patients.
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